RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+4.61%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$870M
AUM Growth
-$103M
(-11%)
Cap. Flow
-$107M
Cap. Flow
% of AUM
-12.27%
Top 10 Holdings %
Top 10 Hldgs %
34.33%
Holding
104
New
12
Increased
20
Reduced
55
Closed
10
Top Buys
| 1 |
Glaukos
GKOS
|
$23M |
| 2 |
Bristol-Myers Squibb
BMY
|
$19.8M |
| 3 |
Elevance Health
ELV
|
$11.2M |
| 4 |
Molina Healthcare
MOH
|
$11.2M |
| 5 |
DexCom
DXCM
|
$10.6M |
Top Sells
| 1 |
Merck
MRK
|
$21.9M |
| 2 |
Inspire Medical Systems
INSP
|
$21.4M |
| 3 |
Cigna
CI
|
$16.5M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$14.7M |
| 5 |
Boston Scientific
BSX
|
$14.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Vir Biotechnology
VIR
$765M
| $1.3M | 0.15% |
+200,000
| New | +$1.3M |
|
77
Alkermes
ALKS
$4.95B
| $1.29M | 0.15% |
39,000
-38,999
| -50% | -$1.29M |
|
78
Kura Oncology
KURA
$732M
| $1.29M | 0.15% |
195,000
-119,526
| -38% | -$789K |
|
79
Arvinas
ARVN
$580M
| $1.28M | 0.15% |
183,000
+27,500
| +18% | +$193K |
|
80
Amgen
AMGN
$153B
| $1.25M | 0.14% |
4,000
+1,000
| +33% | +$312K |
|
81
Geron
GERN
$893M
| $1.24M | 0.14% |
783,000
-217,000
| -22% | -$345K |
|
82
Icon
ICLR
$14B
| $1.22M | 0.14% |
+7,000
| New | +$1.22M |
|
83
Structure Therapeutics
GPCR
$1.14B
| $1.21M | 0.14% |
+70,000
| New | +$1.21M |
|
84
Relay Therapeutics
RLAY
$709M
| $1.21M | 0.14% |
460,000
| – | – |
|
85
Xenon Pharmaceuticals
XENE
$2.99B
| $1.17M | 0.14% |
35,000
| – | – |
|
86
Medpace
MEDP
$13.5B
| $1.16M | 0.13% |
3,800
-3,000
| -44% | -$914K |
|
87
Annexon
ANNX
$225M
| $888K | 0.1% |
460,000
-82,500
| -15% | -$159K |
|
88
Immunocore
IMCR
$1.78B
| $839K | 0.1% |
28,278
-30,000
| -51% | -$890K |
|
89
Avantor
AVTR
$8.74B
| $775K | 0.09% |
47,826
-14,000
| -23% | -$227K |
|
90
IDEAYA Biosciences
IDYA
$2.26B
| $647K | 0.07% |
39,500
-42,500
| -52% | -$696K |
|
91
Apellis Pharmaceuticals
APLS
$3.51B
| $618K | 0.07% |
28,250
-167,341
| -86% | -$3.66M |
|
92
Penumbra
PEN
$10.5B
| $588K | 0.07% |
+2,200
| New | +$588K |
|
93
Repligen
RGEN
$6.54B
| $573K | 0.07% |
4,500
-4,500
| -50% | -$573K |
|
94
Immunovant
IMVT
$2.91B
| $443K | 0.05% |
25,924
-119,076
| -82% | -$2.04M |
|
95
Acadia Healthcare
ACHC
$2.15B
| – | – |
-13,750
| Closed | -$545K |
|
96
Charles River Laboratories
CRL
$7.99B
| – | – |
-14,850
| Closed | -$2.74M |
|
|
IGMS
97
DELISTED
IGM Biosciences
IGMS
| – | – |
-126,064
| Closed | -$770K |
|
98
Novo Nordisk
NVO
$252B
| – | – |
-50,000
| Closed | -$4.3M |
|
99
Pliant Therapeutics
PLRX
$105M
| – | – |
-116,250
| Closed | -$1.53M |
|
100
Stryker
SYK
$149B
| – | – |
-22,500
| Closed | -$8.1M |
|